Biogen/Idec: still a matter of size

Biogen/Idec: still a matter of size
The merger of Biogen and Idec Pharmaceuticals, announced June 23, is likely to help the two relatively isolated companies increase presence in their disease areas. The annual R&D budget for the new pharmaceutical entity, to be called Biogen Idec Inc, will be $500 million, according to company reports.

Leave a Reply

Your email address will not be published. Required fields are marked *

Get email updates

Enter your email address to subscribe to this blog and receive notifications of new posts by email.